MEROPENEM | N215212 | HQ SPECIALTY PHARMA CORP
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Active | Beni-Suef University | 100 | 2025-12-30 → 2026-09-30 | |
| Phase 2 | Active | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | 66 | 2025-06-03 → 2027-07 | |
| Phase 3 | Not Yet Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 168 | 2026-10-01 → 2029-09-30 | |
| Phase 4 | Recruiting | Beneficência Portuguesa de São Paulo | 55 | 2025-03-26 → 2027-12 | |
| Phase 4 | Recruiting | Rambam Health Care Campus | 1,084 | 2019-05-01 → 2027-04-01 | |
| N/A | Recruiting | University Hospital, Ghent | 300 | 2016-08-19 → 2029-07-01 | |
| Phase 4 | Recruiting | University Hospital, Ghent | 58 | 2025-07-09 → 2027-10-01 | |
| Phase 4 | Recruiting | Bassett Healthcare | 852 | 2026-08-17 → 2028-12-31 | |
| Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 48 | 2026-07-21 → 2027-07 | |
| Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 398 | 2026-10-01 → 2028-12 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$119.53
Highest Price
$119.53
FSS NDCs
1
Big4 NDCs
0
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 44567-0402-06MEROPENEM 2GM/VIL INJ | $119.53 | FSS | WG Critical Care, LLC | 06/14/2029 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
10 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Aug 11, 2026 | SUPPL -1 | View Letter (PDF) |
| Dec 4, 2024 | SUPPL -2 | View Letter (PDF) |
| Jul 28, 2023 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.